Tags

Type your tag names separated by a space and hit enter

Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis.
Mayo Clin Proc. 2020 08; 95(8):1621-1631.MC

Abstract

OBJECTIVE

To estimate the prevalence of olfactory and gustatory dysfunctions (OGDs) among patients infected with novel coronavirus disease 2019 (COVID-19).

METHODS

A systematic review was conducted by searching MEDLINE, EMBASE, and the preprint server MedRxiv from their inception until May 11, 2020, using the terms anosmia or hyposmia or dysosmia or olfactory dysfunction or olfaction disorder or smell dysfunction or ageusia or hypogeusia or dysgeusia or taste dysfunction or gustatory dysfunction or neurological and COVID-19 or 2019 novel coronavirus or 2019-nCoV or SARS-CoV-2. The references of included studies were also manually screened. Only studies involving patients with diagnostic-confirmed COVID-19 infection were included. Random-effects meta-analysis was performed.

RESULTS

Twenty-four studies with data from 8438 patients with test-confirmed COVID-19 infection from 13 countries were included. The pooled proportions of patients presenting with olfactory dysfunction and gustatory dysfunction were 41.0% (95% CI, 28.5% to 53.9%) and 38.2% (95% CI, 24.0% to 53.6%), respectively. Increasing mean age correlated with lower prevalence of olfactory (coefficient = -0.076; P=.02) and gustatory (coefficient = -0.073; P=.03) dysfunctions. There was a higher prevalence of olfactory dysfunctions with the use of objective measurements compared with self-reports (coefficient = 2.33; P=.01). No significant moderation of the prevalence of OGDs by sex was observed.

CONCLUSION

There is a high prevalence of OGDs among patients infected with COVID-19. Routine screening for these conditions could contribute to improved case detection in the ongoing COVID-19 pandemic. However, to better inform population screening measures, further studies are needed to establish causality.

Authors+Show Affiliations

Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia.Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia; Monash University, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia.Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia.Department of Epidemiology and Preventive Medicine, Melbourne, Victoria, Australia; Department of Pharmacy, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark. Electronic address: richard.ofori-asenso1@monash.edu.

Pub Type(s)

Journal Article
Meta-Analysis
Systematic Review

Language

eng

PubMed ID

32753137

Citation

Agyeman, Akosua Adom, et al. "Smell and Taste Dysfunction in Patients With COVID-19: a Systematic Review and Meta-analysis." Mayo Clinic Proceedings, vol. 95, no. 8, 2020, pp. 1621-1631.
Agyeman AA, Chin KL, Landersdorfer CB, et al. Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2020;95(8):1621-1631.
Agyeman, A. A., Chin, K. L., Landersdorfer, C. B., Liew, D., & Ofori-Asenso, R. (2020). Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 95(8), 1621-1631. https://doi.org/10.1016/j.mayocp.2020.05.030
Agyeman AA, et al. Smell and Taste Dysfunction in Patients With COVID-19: a Systematic Review and Meta-analysis. Mayo Clin Proc. 2020;95(8):1621-1631. PubMed PMID: 32753137.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis. AU - Agyeman,Akosua Adom, AU - Chin,Ken L, AU - Landersdorfer,Cornelia B, AU - Liew,Danny, AU - Ofori-Asenso,Richard, Y1 - 2020/06/06/ PY - 2020/05/05/received PY - 2020/05/19/revised PY - 2020/05/27/accepted PY - 2020/8/6/entrez PY - 2020/8/6/pubmed PY - 2020/8/15/medline SP - 1621 EP - 1631 JF - Mayo Clinic proceedings JO - Mayo Clin. Proc. VL - 95 IS - 8 N2 - OBJECTIVE: To estimate the prevalence of olfactory and gustatory dysfunctions (OGDs) among patients infected with novel coronavirus disease 2019 (COVID-19). METHODS: A systematic review was conducted by searching MEDLINE, EMBASE, and the preprint server MedRxiv from their inception until May 11, 2020, using the terms anosmia or hyposmia or dysosmia or olfactory dysfunction or olfaction disorder or smell dysfunction or ageusia or hypogeusia or dysgeusia or taste dysfunction or gustatory dysfunction or neurological and COVID-19 or 2019 novel coronavirus or 2019-nCoV or SARS-CoV-2. The references of included studies were also manually screened. Only studies involving patients with diagnostic-confirmed COVID-19 infection were included. Random-effects meta-analysis was performed. RESULTS: Twenty-four studies with data from 8438 patients with test-confirmed COVID-19 infection from 13 countries were included. The pooled proportions of patients presenting with olfactory dysfunction and gustatory dysfunction were 41.0% (95% CI, 28.5% to 53.9%) and 38.2% (95% CI, 24.0% to 53.6%), respectively. Increasing mean age correlated with lower prevalence of olfactory (coefficient = -0.076; P=.02) and gustatory (coefficient = -0.073; P=.03) dysfunctions. There was a higher prevalence of olfactory dysfunctions with the use of objective measurements compared with self-reports (coefficient = 2.33; P=.01). No significant moderation of the prevalence of OGDs by sex was observed. CONCLUSION: There is a high prevalence of OGDs among patients infected with COVID-19. Routine screening for these conditions could contribute to improved case detection in the ongoing COVID-19 pandemic. However, to better inform population screening measures, further studies are needed to establish causality. SN - 1942-5546 UR - https://www.unboundmedicine.com/medline/citation/32753137/Smell_and_Taste_Dysfunction_in_Patients_With_COVID_19:_A_Systematic_Review_and_Meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0025-6196(20)30546-2 DB - PRIME DP - Unbound Medicine ER -